Myeloid Therapeutics develops mRNA-based immunotherapies that utilize in vivo mRNA programming and gene editing to enhance the immune response against cancer and autoimmune diseases. Their therapies aim to improve patient outcomes by harnessing the innate abilities of myeloid cells to target and eliminate malignant cells effectively.
Funding
$135M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer and autoimmune disease treatments often fail to fully harness the body's immune system to effectively target and eliminate malignant cells or address the underlying causes of autoimmune disorders. Traditional cell therapies can be limited by the need for ex vivo cell engineering and may not fully engage the patient's own immune response within the tumor microenvironment.
Solution
Myeloid Therapeutics develops mRNA-based immunotherapies designed to program myeloid cells in vivo, enhancing the immune response against cancer and autoimmune diseases. Their approach leverages the innate abilities of myeloid cells, a key component of the immune system, to directly target and eliminate malignant cells within the body. By utilizing mRNA technology, Myeloid's therapies aim to stimulate a broader anti-tumor adaptive immunity without the need for ex vivo cell engineering. The company's CREATE gene-editing technology also offers the potential for delivering larger genetic sequences into the genome, expanding the possibilities for therapeutic intervention.
Target Audience
The primary target audience includes patients with cancer and autoimmune diseases, as well as healthcare providers and researchers seeking innovative immunotherapeutic approaches.
Features
- In vivo mRNA programming platform to activate myeloid cells within solid tumors.
- CREATE gene-editing technology for delivering large genetic sequences.
- mRNA cell therapy approach to stimulate anti-tumor immunity and alter the tumor microenvironment.
- Therapies designed to improve patient outcomes by harnessing the innate abilities of myeloid cells.
- Focus on developing next-generation immunotherapies for cancer and autoimmune diseases.